A network meta-analysis of first-line treatment options for patients with Child-Pugh class B functional hepatocellular carcinoma: comparison of efficacy and safety
Atezolizumab and bevacizumab combination therapy demonstrated the optimal net benefit regarding PFS and reduced toxicity, whereas lenvatinib monotherapy exhibited the greatest net benefit in OS but with increased toxicity.
Authors
- Zhen-Xin Zeng (ORCID: https://orcid.org/0000-0001-5706-8629)
- Jinqing Wu (ORCID: https://orcid.org/0000-0001-5870-3188)
- Rongjian Pan (ORCID: https://orcid.org/0000-0002-7925-0445)
- Yuxuan Zhang (ORCID: https://orcid.org/0000-0001-9407-9589)
- Xiang-Ye Ou
- Junyi Wu
- Mao-Lin Yan (ORCID: https://orcid.org/0009-0003-5188-6796)
- Yi-Nan Li
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.3389/fphar.2025.1705502
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province
- Fujian Provincial Health Commission